Epinephrine Global Market Report 2024

The epinephrine market size has grown rapidly in recent years. It will grow from $2.44 billion in 2023 to $2.69 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth observed in the historic period in the field of epinephrine can be attributed to several factors. These include the incidence of anaphylaxis, which is a severe and potentially life-threatening allergic reaction, leading to an increased demand for epinephrine as a crucial intervention. Additionally, the presence of a regulatory framework governing the use and availability of epinephrine, the rising prevalence of allergies, efforts in patient education regarding the importance of epinephrine in managing severe allergic reactions, and improved accessibility to epinephrine products have all contributed to the growth during the historic period. These factors collectively influenced the adoption and utilization of epinephrine for emergency medical situations.

The epinephrine market size is expected to see strong growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth in the forecast period in the field of epinephrine can be attributed to several factors. These include the continued rise in allergy rates, initiatives aimed at expanding access to epinephrine, awareness campaigns highlighting the importance of emergency treatment for severe allergic reactions, the exploration of emerging markets, and the development of customized epinephrine delivery systems. Major trends expected in this period include the integration of smart devices in the administration of epinephrine, enhanced education and awareness programs to ensure proper use, the global expansion of access to epinephrine products, regulatory emphasis on product safety standards, and collaborative efforts for research and development in the field. These trends collectively contribute to the evolving landscape of epinephrine use and accessibility in the forecast period.

The escalation in the prevalence of chronic respiratory diseases is expected to drive the growth of the epinephrine market in the foreseeable future. Chronic respiratory diseases encompass a range of medical conditions affecting the lungs and airways, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary sarcoidosis, and pneumoconiosis. These conditions are increasingly prevalent due to various factors such as air pollution and harmful environmental or occupational exposures. Epinephrine, a critical medication used to treat severe asthma attacks and anaphylactic reactions, plays a vital role in managing respiratory distress and life-threatening complications. Globally, chronic respiratory diseases account for a significant portion of non-communicable disease-related deaths, totaling 4.1 million fatalities annually, according to the World Health Organization's September 2023 report. As the incidence of chronic respiratory diseases rises, the demand for epinephrine is expected to grow correspondingly.

The upsurge in healthcare spending is anticipated to be a driving force behind the expansion of the epinephrine market in the coming years. Healthcare expenditure constitutes the total financial investment in healthcare-related goods and services within a specific healthcare system or economy. Increased healthcare expenditure supports the stocking of epinephrine in healthcare facilities such as hospitals, clinics, and emergency medical services. This contributes to wider accessibility of epinephrine auto-injectors or other delivery methods, ensuring availability for individuals with severe allergies. For instance, in November 2022, the Canadian Institute for Health Information reported an increase in healthcare expenditure to $331 billion, a rise of 0.8% compared to the preceding year. This surge, from 7.6% in 2021, underlines the crucial role of escalating healthcare spending in driving the growth of the epinephrine market.

Product innovation stands out as a pivotal trend gaining traction in the epinephrine market. Leading companies in the sector are actively engaged in developing advanced products, including auto-injectors or enhanced delivery mechanisms, to enhance ease of use and fortify their market position. An example of this trend is Baxter International Inc.'s September 2021 launch of Premix Norepinephrine Bitartrate in 5% Dextrose Injection, following approval from the US Food and Drug Administration (FDA). This formulation of norepinephrine bitartrate offers a convenient dosage format in 4 mg/250 mL (16 mcg/mL) and 8 mg/250 mL (32 mcg/mL) for adult patients experiencing severe, acute hypotension, aiding in raising blood pressure effectively.

Major companies in the epinephrine market are actively innovating their product lines, exemplified by the development of OX640, aiming to secure a competitive advantage. OX640 represents a breakthrough in the market, providing a needle-free, user-friendly, and efficient treatment solution for acute allergic reactions, notably anaphylaxis, catering to both community and healthcare settings. In August 2023, Orexo AB, a Sweden-based pharmaceutical company, announced the granting of the first US patent specifically dedicated to OX640 by the United States Patent and Trademark Office (USPTO). This patent signifies a pivotal milestone for Orexo, underscoring the distinctiveness and inventiveness of OX640, particularly its underlying amorphous drug delivery platform, amorphOX. The granted patent in the US not only validates the novelty of the product but also endorses the innovative drug delivery technology behind it.

In November 2021, Marathon Asset Management, LP, a US-based investment management company, completed the acquisition of Kaléo for $310 million. This strategic acquisition aligns with Kaléo's strategic vision of enhancing patient care for individuals at risk of anaphylaxis and other severe life-threatening conditions, leveraging Marathon's proficient management team with expertise in allergists' domain. Kaléo, a US-based pharmaceutical company, is dedicated to pioneering innovative healthcare products, including those related to epinephrine injections, and this acquisition is poised to strengthen its service offerings in the healthcare industry.

Major companies operating in the epinephrine market report are ALK-Abelló A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Abbott Laboratories, Sanofi SA, Viatris Inc., Lincoln Medical Ltd., Kaleo Inc., Gland Pharma Limited, Adamis Pharmaceuticals Corporation, Harvest Pharmaceuticals Inc., Merit Pharmaceutical, Hospira, Inc., Antares Pharma Inc., Bausch & Lomb Incorporated, Novartis AG, Grand Pharma (China) Co. Ltd., Impax Laboratories LLC, Sandoz International GmbH, Tianjin Jinyao Group Co. Ltd., GlaxoSmithKline plc, Amphastar Pharmaceuticals Inc., Par Sterile Products LLC, Amedra Pharmaceuticals LLC, Crossject SA, Halozyme Therapeutics Inc.

North America was the largest region in the epinephrine market in 2023. The regions covered in the epinephrine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epinephrine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of epinephrine formulations include prefilled syringes, auto-injectors, ampoules, and vials. Prefilled syringes are disposable syringes pre-loaded with the medication, designed for self-administration in a single, preloaded dose. This eliminates the need to handle adrenaline ampoules and complete the drawing-up procedure, enhancing convenience and safety. Epinephrine is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used for a range of applications, including the treatment of anaphylaxis (severe allergic reactions), cardiac arrest, superficial bleeding, respiratory disorders, and other emergency situations where the effects of adrenaline are critical for immediate medical intervention.

The epinephrine market research report is one of a series of new reports that provides epinephrine market statistics, including the epinephrine industry's global market size, regional shares, competitors with an epinephrine market share, detailed epinephrine market segments, market trends, and opportunities, and any further data you may need to thrive in the epinephrine industry. This epinephrine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.